CD38 and neoplasm: These include T cell receptor (TCR) knockout and HER2-CAR transduction, and the expression of a novel high-affinity 158V, non-cleavable CD16 Fc receptor to enhance antibody-dependent cellular cytotoxicity (ADCC), CD38 knockout to promote persistence and function in high oxidative stress environments, overexpression of a synthetic IL-7/IL-7 receptor fusion (IL-7RF) and a CXCR2 receptor to respectively promote T-cell stemness and cell trafficking, and finally, it includes a synthetic TGFβ receptor to redirect immunosuppressive signals in the tumor microenvironment.